Aurinia Pharmaceuticals Inc.: Form 10-Q for the period ended Jun 30, 2025
Filed with the SEC on Jul 31, 2025 and accepted by EDGAR at Jul 31, 2025, 06:10 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-04-01 to 2025-06-30 | $70.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2025-01-01 to 2025-06-30 | $132.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2025-04-01 to 2025-06-30 | $7.1m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2025-01-01 to 2025-06-30 | $15.7m | us-gaap:CostOfRevenue |
| Research and development | 3 months2025-04-01 to 2025-06-30 | $7.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2025-01-01 to 2025-06-30 | $13.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-04-01 to 2025-06-30 | $20.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2025-01-01 to 2025-06-30 | $41.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-04-01 to 2025-06-30 | $1.1m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2025-01-01 to 2025-06-30 | $2.2m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2025-04-01 to 2025-06-30 | $643.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2025-01-01 to 2025-06-30 | $1.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-04-01 to 2025-06-30 | $21.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2025-01-01 to 2025-06-30 | $44.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-04-01 to 2025-06-30 | $0.16 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2025-01-01 to 2025-06-30 | $0.32 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-04-01 to 2025-06-30 | $0.16 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2025-01-01 to 2025-06-30 | $0.33 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-04-01 to 2025-06-30 | 137,526,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2025-01-01 to 2025-06-30 | 140,193,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2025-01-01 to 2025-06-30 | $45.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Share repurchases | 6 months2025-01-01 to 2025-06-30 | $89.5m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2025-06-30 | $52.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-30 | $409.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-30 | $502.6m | us-gaap:Assets |
| Current liabilities | At period end2025-06-30 | $78.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-30 | $167.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-06-30 | $335.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001600620-25-000092. Last ingested by Listed: Oct 30, 2026, 08:08 ET. Listed shows no prices and gives no investment advice.